Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDI-L213
- Development stage
- Preclinical
- Lead developer
- Empire Discovery Institute
- Modality
- Peptides
01
Overview
EDI-L213 is a preclinical peptide-based therapeutic candidate developed by the Empire Discovery Institute (EDI) for the treatment of diabetic kidney disease (DKD). The drug functions by modulating a specific profibrotic mechanism within renal mesangial cells, aiming to mitigate the fibrotic processes that lead to glomerular damage and end-stage renal disease in diabetic patients. According to the developer's pipeline, EDI-L213 has been out-licensed to a third party for further development and is currently in the preclinical stage.
- Other names
- EDI-L213EDI-L-213EDI-L 213
Beyond the preview
Go deeper on EDI-L213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDI-L213.